AIREDALE NHS Foundation Trust has earned recognition for its involvement in trials of a drug which aims to help patients with severe Covid-19 symptoms.
The trust has been acknowledged in the acclaimed global medical publication, the New England Journal of Medicine.
Airedale was among 175 NHS organisations in the UK which took part in the trials for Dexamethasone.
The research was hailed as a huge success, with results showing that the drug can significantly improve outcomes for some of the most severely-ill hospitalised patients.
Nineteen patients were recruited at Airedale, where the principal investigator was ICU consultant Dr Tamsin Gregory.
Working alongside her was senior research sister Emma Dooks, who said: “It was a privilege to be part of this national research trial – and we are proud that the work has been acknowledged. We can now use these positive results to treat coronavirus patients and manage the pandemic going forward. Thank you to all patients who took part.”
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here